At about 34.30 of the webcast, Prof. Packham clearly states that...

At about 34.30 of the webcast, Prof. Packham clearly states that there was no increase in Albuminuria for the sub group <57mg/mmol. They lowered the threshold for patient inclusion to about 30mg/mmol. compared to other trials. You have to realize that all 40 patients were already being treated on the current standard of care(placebo) for CKD/DKD. For the sub group with >57mg/mmol, DMX200 showed an additional(over placebo) benefit of reduction in albuminuria by 18% for 26 patients(64% of 40 patients); a reduction of 25% for 56%(22 patients) and a reduction of 30% for 25%(10 patients). This is basically the sub group results at date of announcement. Further sub group analysis is to come. The legacy effect will probably increase the reduction in albuminuria(from DMX200) as there was a benefit in taking DMX200 and this would show up over time(about 3 months?).